Novartis. financial afternoon. third to in this with this widely, quarter signing of Thanks, start first the at here XXXX licensing addition CodeEvolver Please I'm and off you filed the thank refer announcing X-K thrilled platform deal, afternoon, Today, strong to Jody. Codexis. solid everyone, detail Good a and for joining great our also strategic time to to We're in results us. progress
growing and the each and patent have These worldwide. invest XX benefits that our team in-house, them, technologies Now sustainability drug to GSK global of XXX bringing our like top stay liberate similarly over network engineering great partners these saving great cover platform are Novartis, come. exploit manufacturing. applicable issued and platform protein for of the is Codexis, widely other pharmaceutical assured is the CodeEvolver licensing and pharma engineering three unique the scientific the available CodeEvolver benefits applications protein-based for in chosen access technology to at patents cost out catalysis Merck to a from companies CodeEvolver Novartis to This vanguard validating our to license structured them options access had Codexis. Combined how in platform years at of before them all partnered chose deal substance to many with growing licensing with protein CodeEvolver deals. and to to
performance or Novartis. The is in enzymes for of substances drug and use use owned exclusive for to as take enzymes for commercialize technology to most me a develop few platform you. Novartis proprietary important The nonexclusively CodeEvolver the set our novel by license the catalyst elements protein manufacture agreement their the engineering manufacture up Novartis for controlled highlight in-house Let enables pharmaceutical use development novel and minutes of by products. for and to research, research,
ownership platform with CodeEvolver our created improvements the retain technology, As will all of Novartis. by full Codexis deals, including may be that of
transfer have established At at technology Switzerland running lab months activity. completion and transferring its the Novartis and in team we executed comprised XX on be of of three of will planned training CodeEvolver the independently. CodeEvolver initiate agreement, with maximum proficient Now period Novartis' a and commissioned technology. platform tech that last the transfer, we've the Novartis to The will platform will waves of is
additional be an tech already, combine payment payment million. additional followed two transfer, $X For a triggered and to by $X opportunities has tech will Codexis milestone upfront transfer million that that
to purchase of Following transfer, completion multiyear has agreed period. tech improvements a Novartis the CodeEvolver over
a these payments would we annual transaction earn spread for deals, to will the I Codexis million period, that our financial $XX CodeEvolver this front-end with enabling more of highlight to that bridge, Novartis two total. stable payments improvements total $X million like to economics payment prior more combine this Comparing structure in wait in are the upfront back-end and while kick time, over milestone in. much During
each usage the Novartis is back-end deal using economics, the deal substance back-end opportunity improvement the the that drug Novartis Regarding Codexis payment is structure modeled some Novartis The no by the throughout begin caps and is successful Novartis, the substance. created negotiated of the usage stage these dollar can life in are or drug payments. payments. for key each clinical nice There CodeEvolver with from Merck for the protein the kilogram payments deal for using Novartis to of of refer produced limits used a features. commercial as in usage These these drugs extend to We license. affected will
to Novartis bioconjugated that create on using of CodeEvolver or has prior that Novartis after Merck efficient and developed able commercialize Codexis preferentially setting compound. similar deal, conjugated the drug preferential supply to and to Novartis Codexis of can without create focuses The proteins I molecule deals completes the earlier ingredients. opportunity drug's substances This some biologic the a of up the with protein using earlier supply approval. a is and types these five catalyst pharmaceutical In extends creates base to the includes catalyst trial for enable also manufacture addition license. after to be drug rights protein a commercialize reacted Novartis starts small than sees Novartis catalysts small value for to the agreement where for molecule Phase protein proof-of-concept deal to processes. years and drug in
Codexis. that, development own to and such Novartis processes, continued It Codexis can not as higher. Codexis' a with but is and commercialization and agreement. right would of important for the use commercialize note proteins Novel perform usage Novartis be part CodeEvolver developing to research to given therapeutic significantly of also require agents, success Biotherapeutics, granted discovering payment as Novel For have in this we growing will new such Biotherapeutics, a agreement our development early to
with Novartis. Our super this Codexis at chapter entire about team new is excited
following embrace a work platform then has for build while by a of a dedicated the license a in Novartis for platform XX path the first of of to time too, we justification this all that the us, Reinforcing of elements nicely encourages installation will the course first leading taken to over followed has team protein future. the stream track growing business business and other very project their with with first been required project dedicated the this companies order it year. awareness quarter While It natural a Other technology, engineering pharmaceutical in time our deal are one. pharma partnerships on team, Codexis' of for that which this top pharmaceutical currently to big another well. a its CodeEvolver installed us leader license advancing follow Other investment. in are point, as
Given just a to I time two the highlights year-end and Novartis in over months spent quick progress. today XXXX on illustrate continued will our objectives new important detailed transaction set quarterly ago the strategic provide just widespread of our I this call,
multiyear Tate week, enzyme start partner Lyle. our with the of food & agreement supply announced licensing last whereas sector, we a me Let signing the with and
novel covers nutrition TASTEVA initial zero-calorie Lyle's of Stevia M agreement & the manufacture at M this new branded commercially available. bakery products already Tate as know, M. developed enzymes, with better-tasting, of are Lyle interest formulated with in in a suite sweetener Codexis you reports TASTEVA & customer some As Tate performance used that TASTEVA strong and
exemplifies portfolio. for is We TASTEVA from our partners, do speed reach products that enzymes innovation expect what opportunities, of executive all the of I the M and both time & press the market We & leveraging model speed loved release and and over hallmark capabilities Tate quote global revenue-producing leading become Performance together among Codexis." partnership a manufacturing technological with our Tate we for "The try to of Enzyme Lyle's markets. will quote, our and in the the with in partnerships of Lyle unique and This
food this quote, new highlights industry. candidate projects and XX% have Sciences impact that built follow year-over-year Tate product from revenue over for also Other industrial treatment revenue the We used as Merck, & Lyle the year, me partner that six for digit bladder. of that in aspire new saw and its each strength quarter those a a product excess time first quoting with vibegron, Urovant we by the to of proprietary and new each enzyme of product in applications. develop similar in with three opportunities for Let landed to customer growth, manufacture was in QX led so we the overactive far partnerships performance highlighting million $X
for their for announced sales Urovant world Rounding line bladder results last marketing a rest to Pharma Japan. announced and You vibegron with for the the KYORIN outside in supplying Japan which same III future enzyme agreement supply the positive may with the performance well China. rights holds bodes of we XXXX. much ligase in month, Urovant product a top on year. continue second this report enzyme Phase profitable successfully vibegron as recall, offering, in sequencing launch to months, remain this but growing readying penetrate sales in are Enzymes to past Not in Performance our our segment, with this two next-generation in over we new and out markets track for DNA later establishing vertical DNA our sector the polymerase we overactive
we two as goal rest year-to-date on exclusive been Nestle the the Biotherapeutics of status segment late Science or progress is beyond well. PKU as million for option encouraging Biotherapeutic partnerable the us during to PKU exercised solid Novel generating to significant have work added our solid for plus phenylketonuria Health additional for progress the we recognition a collaborating $X The deliver pipeline license revenue by XXXX. making our event will that reach therapeutic its revenue making Novel discovery R&D CDX-XXXX the have management well, programs on. Finally, of is quarter,
over QX turn more the to provide Let me our financial to on Gordon Gordon? call results. details now
